MedPage Today brought together three expert leaders for a virtual roundtable discussion on the joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple sclerosis ...

Living with a chronic, progressive condition such as secondary progressive multiple sclerosis (SPMS) can affect both your physical and mental health. SPMS results in a gradual decline in function over ...

Immunic Therapeutics was granted a patent in Europe that protects all dosing regimens of its MS therapy vidofludimus calcium through 2038.

The use of ibudilast in the treatment of progressive multiple sclerosis (MS) has been suggested to reduce lesion volume in patients. Ibudilast intervention in patients with progressive multiple ...

Scientists have uncovered two closely related cytokines -- molecules involved in cell communication and movement -- that may explain why some people develop progressive multiple sclerosis (MS), the ...

- Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment - - Phase III studies for fenebrutinib in ...

Finally, a family friend who worked as a healthcare provider in urgent care took her concerns seriously, ordered tests, and asked if she’d ever had an MRI. Within a month, Chelsea had her first scan ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.